arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

CryoPort, Inc.

CYRX Health Care Biotechnology: Pharmaceutical Preparations
$15.81
Today
as of Sep 4, 16:48 ET
Last 30 days +4.22% Jul 28 → Sep 04
$14.52 $15.22 $15.92 $16.62 $17.32 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$15.65
High
$15.99
Low
$15.49
Volume
$314,164
Avg Vol
$598,397
Mkt Cap
$766M
P/E (TTM)
—
Beta
—
52w High
$17.20
52w Low
$7.61
Div Yield
—
Shares Out
$51M

Recent Press Releases & News last 60 days · 11 items

Aug 24 · 04:29 Simply Wall St.
Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Growth Assumptions
Aug 14 · 04:28 Motley Fool
Cryoport (CYRX) Q2 2026 Earnings Call Transcript
Aug 11 · 16:00 Zacks
CryoPort (CYRX) Upgraded to Buy: Here's Why
▸ Show all 11 press releases & news Free account →

Overview

52-week range
$7.61
$17
86% of range
Avg surprise (last 3)
-18.6%
Avg reaction (last 2)
+0.4%
50% positive
Latest IV / EM
55%
EM ±8.5% · $15 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.62$-1.22$-0.82$-0.42$-0.02 Actual $-0.16Actual $-0.42Actual $-0.31Actual $-0.43Actual $-1.62Actual $-0.02Actual $-0.22Est $-0.23Actual $-0.29Est $-0.20Actual $-0.18Actual $-0.23Est $-0.20Actual $-0.20 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-12M$20M$51M$83M$114M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.20 — — — — financials
Mon May 4, 2026Mar/2026 $-0.23 $-0.20 -15.0% -4.5% -1.4% earnings
Tue Sep 30, 2025Sep 2025 $-0.18 — — — — financials
Tue Aug 5, 2025Jun/2025 $-0.29 $-0.20 -45.0% — — earnings
Wed May 7, 2025Mar/2025 $-0.22 $-0.23 +4.3% — +2.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.02 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.62 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.43 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.31 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.42 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.16 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$49M$48M—$44M$45M$41M—$38M
Cost of revenue$26M$26M—$23M$24M$22M—$21M
Gross profit$23M$22M—$21M$21M$19M—$17M
Operating income$-10M$-10M—$-10M$-10M$-7M—$-13M
Net income$-8M$-11M—$-7M$109M$-12M—$805,000
EPS (diluted)$-0.20$-0.25—$-0.18$2.13$-0.28—$-0.02

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$269M$273M$250M$256M$243M$36M$34M$31M
Inventory$22M$22M$23M$23M$23M$23M$21M$24M
Total current assets$460M$471M$476M$485M$489M$411M$342M$350M
Total assets$756M$764M$765M$774M$774M$700M$703M$702M
Long-term debt————————
Total liabilities$266M$269M$262M$261M$259M$301M$302M$283M
Total equity$491M$495M$503M$513M$519M$399M$402M$419M

Implied volatility — last 90 days

29%132%235%338%441% Jun 07 — IV 108% · EM ±15.0%Jun 08 — IV 93% · EM ±12.3%Jun 09 — IV 95% · EM ±11.8%Jun 10 — IV 54% · EM ±6.4%Jun 11 — IV 113% · EM ±12.5%Jun 12 — IV 80% · EM ±8.2%Jun 19 — IV 54% · EM ±11.8%Jun 22 — IV 65% · EM ±13.5%Jun 23 — IV 58% · EM ±11.9%Jun 24 — IV 61% · EM ±12.2%Jun 25 — IV 81% · EM ±15.9%Jun 26 — IV 64% · EM ±12.3%Jun 29 — IV 128% · EM ±22.7%Jun 30 — IV 78% · EM ±13.4%Jul 01 — IV 68% · EM ±11.3%Jul 02 — IV 76% · EM ±12.2%Jul 03 — IV 80% · EM ±12.4%Jul 06 — IV 72% · EM ±10.0%Jul 07 — IV 58% · EM ±7.6%Jul 08 — IV 64% · EM ±8.0%Jul 09 — IV 66% · EM ±7.8%Jul 10 — IV 134% · EM ±14.8%Jul 13 — IV 136% · EM ±11.3%Jul 14 — IV 202% · EM ±14.6%Jul 15 — IV 296% · EM ±17.5%Jul 16 — IV 327% · EM ±13.6%Jul 20 — IV 78% · EM ±18.5%Jul 21 — IV 87% · EM ±20.2%Jul 22 — IV 71% · EM ±16.1%Jul 23 — IV 96% · EM ±21.5%Jul 24 — IV 76% · EM ±16.8%Jul 27 — IV 79% · EM ±16.5%Jul 28 — IV 72% · EM ±14.8%Jul 29 — IV 89% · EM ±17.7%Jul 30 — IV 88% · EM ±17.3%Jul 31 — IV 106% · EM ±20.4%Aug 03 — IV 78% · EM ±13.9%Aug 04 — IV 88% · EM ±15.1%Aug 05 — IV 86% · EM ±14.4%Aug 06 — IV 73% · EM ±11.8%Aug 07 — IV 63% · EM ±9.9%Aug 10 — IV 66% · EM ±9.1%Aug 11 — IV 73% · EM ±9.7%Aug 12 — IV 55% · EM ±6.9%Aug 13 — IV 60% · EM ±7.1%Aug 14 — IV 30% · EM ±3.3%Aug 17 — IV 63% · EM ±5.2%Aug 18 — IV 69% · EM ±5.0%Aug 19 — IV 441% · EM ±26.1%Aug 20 — IV 394% · EM ±16.5%Aug 24 — IV 67% · EM ±14.1%Aug 25 — IV 61% · EM ±12.6%Aug 26 — IV 108% · EM ±21.7%Aug 27 — IV 55% · EM ±10.7%Aug 28 — IV 86% · EM ±16.5%Aug 31 — IV 74% · EM ±13.1%Sep 01 — IV 77% · EM ±13.3%Sep 02 — IV 54% · EM ±9.0%Sep 03 — IV 50% · EM ±8.0%Sep 04 — IV 55% · EM ±8.5%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in